Saturday, March 29 2014: St Jude Medical announced the CE mark approval and European launch of its Prodigy chronic pain system with burst technology. As the first and only implantable neuromodulation system that delivers burst stimulation, the Prodigy system is designed to reduce pain, improve patient satisfaction and allow reduced paraesthesia. The new device offers patients traditional tonic spinal cord stimulation in addition to burst technology for improved stimulation options.
“Burst technology expands treatment options for patients suffering from chronic pain and provides significant relief so they can reclaim their quality of life,” says Dirk De Ridder, neurological professor of Neurosurgery, from the University of Otago in Dunedin, New Zealand. “Prodigy’s pioneering stimulation mode allows me to tune therapy to my patient’s unique pain condition. Burst holds promise to...
News from the industry
Friday, July 19 2013: St. Jude Medical Inc. (STJ) has agreed to invest $40 million in a privately held medical device company that developed a new pain management therapy, gaining the right to exclusively distribute the system and potentially acquire the company. The Menlo Park, Calif.-based Spinal Modulation Inc. has developed a type of neuromodulation therapy that provides a new pain management option for patients with chronic, intractable pain. The Axium Neurostimulator System works through stimulation of the dorsal root ganglion, which are small structures that contain nerve fibers, which carry signals to the brain. The agreement gives St. Jude an exclusive option to distribute the Axium system in international markets where it is approved for sale. St. Jude Medical will also have the exclusive option to acquire the company for up to $300 million plus certain revenue-based milestones following U.S....
Sunday, June 2 2013: In June 2013, Medtronic, Inc. (NYSE: MDT) initiated four medical device notifications to customers worldwide about the SynchroMed® Implantable Infusion System. These notifications provide clinicians with information to help identify and manage issues that impact the safe and reliable delivery of therapy using the SynchroMed Implantable Infusion System. The United States Food and Drug Administration (FDA) has classified three of these notifications as Class I recalls.The fourth notification is an update to a 2011 action related to pump refill which was previously classified by the FDA as a Class I recall. Patients are encouraged to maintain regular follow-up appointments with their physicians; however, if they experience a change or return of symptoms or hear a device alarm, they should contact their physician immediately. No action is required of physicians beyond the...
